TSXV:ARCH - Post Discussion
Post by
Viking2233 on Aug 02, 2024 10:00am
Arch is the real Deal
And they have the science and the data to prove it! The Canadian government just doesn’t hand out grants to anyone. You don’t get asked to participate in a Pontiac trial unless you are the real deal.
We have one active phase 2 trial that has been dosing in Turkey for over 5 months. This is extremely positive and I would suspect we are close to announcing a signal. I have no idea how many patients have been dosed but conservatively speaking 1 patient per week per site would have us at 5 per week x 22 weeks =110 dosed.
I believe 100 patients is a very good indication of how Metablok is working. There have been no news releases indicating any adverse reactions, so safe to assume as we continue to dose the risk of using Metablok is reduced which should reflect in share price.
I believe the fall of 2024 should be a turning point for Arch once we get through the slow summer months. As each day and week passes we get closer to completing our AKI Phase 2 Trial and closer to data being released.
The stars are aligning but Management needs to ramp up communication and get in-front of big money to generate buying. Once we see a big uptick in volume and buyers the share price will rocket up but we need to get the story out there, outlining the incredible investment opportunity!
Be the first to comment on this post